We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Development of Spinal Enthesopathies in Adults With X-linked Hypophosphatemia.
- Authors
Herrou, Julia; Fechtenbaum, Jacques; Rothenbuhler, Anya; Kamenický, Peter; Roux, Christian; Linglart, Agnès; Briot, Karine
- Abstract
Context: Musculoskeletal complications are the main manifestations in adults with X-linked hypophosphatemia (XLH). Enthesopathy significantly impairs quality of life. Objective: To identify the risk factors associated with the development and progression of spinal enthesopathies in adults with XLH. Design and setting: We conducted a retrospective study in the French Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism. Patients: Adults XLH patients with 2 EOS® imaging performed at least 2 years apart at the same center between June 2011 and March 2022. The progression of enthesopathies was defined as a new enthesopathy at least 1 intervertebral level in patients with or without presence of enthesopathy at baseline. Main outcome measures: Demographic, treatment, PHEX mutation with the progression of enthesopathies. Results: Fifty-one patients (66.7% of women, mean age 42.1 ± 13.4 years) underwent 2 EOS imaging with an average interval of 5.7 (± 2.31) years. Progression of spinal enthesopathies was observed in 27 (52.9%) patients. In univariate analysis, patients with a progression of spinal enthesopathies were significantly older (P< .0005), were significantly older at treatment initiation (P = .02), presented with dental complications (P = .03), received less frequently treatment during childhood with phosphate and/or vitamin D analogs (P = .06), and presented more frequently with hip osteoarthritis (P = .002) at baseline. In multivariate analysis, none of these factors was associated with a progression of spinal enthesopathies. Conclusion: This study confirms the high proportion of patients with a progression of spinal enthesopathies. Age seems to be the main factor associated with progression.
- Subjects
HYPOPHOSPHATEMIA; PHOSPHATE metabolism
- Publication
Journal of Clinical Endocrinology & Metabolism, 2023, Vol 108, Issue 12, pe1524
- ISSN
0021-972X
- Publication type
Article
- DOI
10.1210/clinem/dgad383